Analysts Set Expectations for Atossa Genetics Q1 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Atossa Genetics in a research note issued to investors on Wednesday, November 12th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.08) per share for the quarter. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.33) EPS.

A number of other equities research analysts also recently issued reports on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, October 8th. Ascendiant Capital Markets upped their price target on shares of Atossa Genetics from $7.50 to $7.75 and gave the stock a “buy” rating in a research note on Monday, September 22nd. Finally, Zacks Research cut Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Atossa Genetics has a consensus rating of “Hold” and an average target price of $6.25.

Atossa Genetics Stock Performance

ATOS stock opened at $0.80 on Monday. The firm has a 50 day simple moving average of $0.90 and a 200 day simple moving average of $0.86. Atossa Genetics has a 52 week low of $0.55 and a 52 week high of $1.40. The stock has a market cap of $103.34 million, a P/E ratio of -3.48 and a beta of 0.99.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07).

Hedge Funds Weigh In On Atossa Genetics

Several institutional investors have recently bought and sold shares of ATOS. Vanguard Group Inc. boosted its stake in shares of Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics in the 2nd quarter valued at approximately $2,468,000. Jane Street Group LLC acquired a new stake in Atossa Genetics in the 2nd quarter worth approximately $381,000. Charles Schwab Investment Management Inc. boosted its position in Atossa Genetics by 40.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock worth $284,000 after purchasing an additional 120,934 shares during the period. Finally, Qube Research & Technologies Ltd boosted its position in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after purchasing an additional 325,340 shares during the period. 12.74% of the stock is currently owned by institutional investors.

About Atossa Genetics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.